ArticleArchives of virology2025
Identification of a recombinant GII.13[P21] norovirus strain: molecular dynamic simulations indicate that gene mutations shifted its spectrum of binding to host receptor glycans.
Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A single amino acid in the viral capsid makes a major contribution to the interaction between human norovirus GII.6 and the bacterial Psl exopolysaccharide.Applied and environmental microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Human norovirus is a pervasive pathogen that causes global outbreaks of viral gastroenteritis. Previous studies have suggested that histo-blood group antigens (HBGAs) can interact with human norovirus, facilitating its entry of host cells and significantly affecting its evolution. In this study, the complete genome sequence of recombinant GII.13[P21] norovirus from fecal samples was analyzed. Molecular dynamics simulations of GII.13 norovirus P proteins from 1978 to 2019 showed changes in their capacity to bind to HBGAs. Initially, GII.13 proteins bound A or B/H-type HBGAs, but subsequent mutations resulted in a loss of this binding capacity, favoring binding to the HBGA type I precursor (Lewis c) over A or B/H and Lewis antigens.
Indexed as
Identifiers
40169405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.